Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

Abstract

The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.

What is claimed is: 
     
         1 . A method for treating ADHD or a related behavioral disorder in a subject comprising administering to a subject in need of treatment for ADHD or a related behavioral disorder a pharmaceutical composition comprising an effective amount of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein the ADHD is selected from the group consisting of Attention Deficit Hyperactivity Disorder-predominantly hyperactive-impulsive subtype, Attention Deficit Hyperactivity Disorder-predominantly inattentive subtype, and Attention Deficit Hyperactivity Disorder-combined subtype. 
     
     
         3 . The method according to  claim 1 , wherein the related behavioral disorder is selected from the group consisting of Conduct Disorder and Oppositional Defiant Disorder. 
     
     
         4 . The method according to  claim 1 , wherein the subject is a human child, adolescent, or adult. 
     
     
         5 . The method according to  claim 4 , wherein the subject is an adult. 
     
     
         6 . The method according to  claim 4 , wherein the subject is a child. 
     
     
         7 . The method according to  claim 1 , wherein the pharmaceutical composition further comprises an additional psychotherapeutic agent, wherein the additional psychotherapeutic agent is an antidepressant, anti-psychotic, anti-convulsant or anxiolytic agent. 
     
     
         8 . The method according to  claim 7 , wherein the additional psychotherapeutic agent is a tri-cyclic antidepressant, specific monoamine reuptake inhibitor, selective serotonin reuptake inhibitor, selective norepinephrine or noradrenaline reuptake inhibitor, selective dopamine reuptake inhibitor, multiple monoamine reuptake inhibitor, monoamine oxidase inhibitor, atypical antidepressant, atypical antipsychotic, or anticonvulsant. 
     
     
         9 . The method according to  claim 1 , wherein the effective amount is effective to decrease ADHD symptoms. 
     
     
         10 . The method according to  claim 9 , wherein the effective amount is effective to decrease the subject's score on an ADHD rating scale. 
     
     
         11 . The method according to  claim 1 , wherein the (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than 2% w/w of the corresponding (−) enantiomer. 
     
     
         12 . The method according to  claim 1 , wherein the (1R,55)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than 1% w/w of the corresponding (−) enantiomer. 
     
     
         13 . The method according to  claim 1 , wherein the pharmaceutically acceptable salt is a hydrochloride salt. 
     
     
         14 . A method for treating a substance abuse disorder in a subject comprising administering to a subject in need of treatment for a substance abuse disorder a pharmaceutical composition comprising an effective amount of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. 
     
     
         15 . The method according to  claim 14 , wherein the substance abuse disorder is selected from the group consisting of alcohol-related disorders, nicotine-related disorders, amphetamine-related disorders, methamphetamine-related disorders,  cannabis -related disorders, cocaine-related disorders, hallucinogen-use disorders, inhalant-related disorders, and opioid-related disorders. 
     
     
         16 . The method according to  claim 14 , wherein the (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than 2% w/w of the corresponding (−) enantiomer. 
     
     
         17 . The method according to  claim 14 , wherein the (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than 1% w/w of the corresponding (−) enantiomer. 
     
     
         18 . The method according to  claim 14 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.